Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Show full item record



Permalink

http://hdl.handle.net/10138/304958

Citation

Kreutzman , A , Yadav , B , Brummendorf , T H , Gjertsen , B T , Lee , M H , Janssen , J , Kasanen , T , Koskenvesa , P , Lotfi , K , Markevärn , B , Olsson-Stromberg , U , Stentoft , J , Stenke , L , Söderlund , S , Udby , L , Richter , J , Hjörth-Hansen , H & Mustjoki , S 2019 , ' Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line ' , OncoImmunology , vol. 8 , no. 9 , e1638210 . https://doi.org/10.1080/2162402X.2019.1638210

Title: Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
Author: Kreutzman, Anna; Yadav, Bhagwan; Brummendorf, Tim H.; Gjertsen, Bjorn Tore; Lee, Moon Hee; Janssen, Jeroen; Kasanen, Tiina; Koskenvesa, Perttu; Lotfi, Kourosh; Markevärn, Berit; Olsson-Stromberg, Ulla; Stentoft, Jesper; Stenke, Leif; Söderlund, Stina; Udby, Lene; Richter, Johan; Hjörth-Hansen, Henrik; Mustjoki, Satu
Contributor organization: Department of Clinical Chemistry and Hematology
Immunobiology Research Program
Hematologian yksikkö
University of Helsinki
HUS Comprehensive Cancer Center
University Management
Date: 2019-09-02
Language: eng
Number of pages: 13
Belongs to series: OncoImmunology
ISSN: 2162-402X
DOI: https://doi.org/10.1080/2162402X.2019.1638210
URI: http://hdl.handle.net/10138/304958
Abstract: Changes in the immune system induced by tyrosine kinase inhibitors (TKI) have been shown to positively correlate with therapy responses in chronic myeloid leukemia (CML). However, only a few longitudinal studies exist and no randomized comparisons between two TKIs have been reported. Therefore, we prospectively analyzed the immune system of newly diagnosed CML patients treated with imatinib (n = 20) or bosutinib (n = 13), that participated in the randomized BFORE trial (NCT02130557). Comprehensive immunophenotyping, plasma protein profiling, and functional assays to determine activation levels of T and NK cells were performed at diagnosis, 3, and 12 months after therapy start. All results were correlated with clinical parameters such as Sokal risk and BCR-ABL load measured according to IS%. At diagnosis, low Sokal risk CML patients had a higher frequency of cytotoxic cells (CD8 + T and NK cells), increased cytotoxic potential of NK cells and lower frequency of naive and central memory CD4 + T cells. Further, soluble plasma protein profile divided patients into two distinct clusters with different disease burden at diagnosis. During treatment, BCR-ABL IS% correlated with immunological parameters such as plasma proteins, together with different memory subsets of CD4+ and CD8 + T cells. Interestingly, the proportion and cytotoxic potential of NK cells together with several soluble proteins increased during imatinib treatment. In contrast, no major immunological changes were observed during bosutinib treatment. In conclusion, imatinib and bosutinib were shown to have differential effects on the immune system in this randomized clinical trial. Increased number and function of NK cells were especially observed during imatinib therapy.
Subject: CML
imatinib
bosutinib
Sokal
BCR-ABL
CHRONIC MYELOID-LEUKEMIA
NK-CELLS
INHIBITORS IMATINIB
T-CELLS
NILOTINIB
DASATINIB
DISCONTINUATION
MANAGEMENT
MONOCYTES
RESPONSES
3122 Cancers
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Immunological_m ... or_imatinib_first_line.pdf 6.053Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record